Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome

Kim L. Brunekreefta Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Sterre T. Paijensa Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Maartje C.A. Woutersb Trev and Joyce Deeley Research Centre, BC Cancer, BC Cancer, Victoria, Canada

Fenne L. Komdeura Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Florine A. Egginka Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Joyce M. Lubbersa Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Hagma H. Workela Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Elisabeth C. Van Der Slikkea Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Noor E.J. Pröppera Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Ninke Leffersa Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Julien Adamc Department of Clinical Biology, Institut De Cancérologie Gustave Roussy, Paris, France

Harry Pijpera Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Annechien Plata Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Arjan Kola Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

Hans W. Nijmana Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The NetherlandsCorrespondence[email protected]

https://orcid.org/0000-0002-1821-3042

Marco De Bruyna Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, The Netherlands

show all

Figures & data

Figure 1. Immune contexture is defined by the tissue of origin, independent of chemotherapy.

Figure 2. Immune cell distribution is comparable between pre- and post-chemotherapy tumors. (a) Epithelial infiltration of CD3⁺, CD8⁺, CD27⁺, PD1⁺, FoxP3⁺, and CD20⁺ cells in pre- and post-chemotherapy tumors. Density is defined as cells/mm². (b) Stromal infiltration of CD3⁺, CD8⁺, CD27⁺, PD1⁺, FoxP3⁺, and CD20⁺ cells in pre- and post-chemotherapy tumors. Density is defined as cells/mm². (c) Epithelial and stromal infiltration of CD16⁺ cells in pre- and post-chemotherapy tumors. Epithelial infiltration was determined by density in cells/mm², stromal infiltration was determined by the percentage of positive area. (d) Epithelial infiltration of CD11 c⁺, LAMP3⁺, CD68⁺, and CD163⁺ cells in pre- and post-chemotherapy tumors. Density is defined as cells/mm². (e) Stromal infiltration of CD11 c⁺, LAMP3⁺, CD68⁺, and CD163⁺ cells in pre- and post-chemotherapy tumors. Stromal infiltration is determined by the percentage of positive area. (f) Epithelial and stromal infiltration of PD-L1⁺ cells in pre- and post-chemotherapy tumors. Infiltration was determined by the percentage of positive area. (a–f) Representative samples are depicted in supplementary figure S5. Differences in the number of tumor-infiltrating immune cells on FFPE slides were determined by two-tailed Mann Whitney test. N-numbers are described in supplementary table S3 C. G, Median immune cell density of all epithelial and stromal immune cells depicted in a–f. Comparability between pre- and post-chemotherapy tumors was determined by a Pearson correlation test. R² = 0.92, <0.0001.